Author

Yiran Wang

Observed names: Y. Wang, Yiran WANG

Institutions: Shenzhen University, Shenzhen University Health Science Center, Second Affiliated Hospital of Zhejiang University, Zhejiang University

Observed institutions: Shenzhen University, Lanzhou University Second Hospital, Peking University First Hospital, Shenzhen University Health Science Center, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Lanzhou University

ORCID: 0009-0009-5190-5145

Observed ORCID: 0009-0009-5190-5145

OpenAlex ID: A5032948516

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial

2024 · Lixin Wang, Chuling Fang, et al. · Blood Cancer Journal · 40

The role of gut microbiota involved in prostate microenvironment and symptoms improvement in chronic prostatitis/chronic pelvic pain syndrome patients treated with low‐intensity extracorporeal shock wave

2024 · Xiangbin Kong, Zhilong Dong, et al. · The Prostate · 7

Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma

2025 · Chuling Fang, Lixin Wang, et al. · Journal of Translational Medicine · 4

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin’s lymphoma

2026 · Lixin Wang, Chuling Fang, et al. · Journal for ImmunoTherapy of Cancer · 2

Advances in surgical treatment of hidradenitis suppurative

2023 · Yiran WANG, Chunmao HAN, et al. · Journal of Zhejiang University (Medical Sciences) · 1

283 Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment

2023 · Y. Gao, Y. Wang · Journal of Investigative Dermatology · 1

Sequential targeted therapy for anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a case report

2026 · Guocheng Zhong, Yiran Wang, et al. · Frontiers in Medicine

AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness

2026 · Shuyi Li, Shujiao He, et al. · Proceedings of the National Academy of Sciences

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

2026 · Zefeng Xu, Jinqin Liu, et al. · Blood Cancer Journal

Self-Assembly of Human Embryonic-Stem-Cell-Derived Keratinocytes and Fibroblasts into 3D Spheroid Structures for Epidermal Regeneration In Vivo

2026 · Chenghao Cai, Huan Liu, et al. · Cells

Custom-made cervical orthosis for pediatric neck scar contracture: a self-controlled case series

2026 · Yiran Wang, Shulei Mao, et al. · BMC Pediatrics

Works count: 11

Citation count: 55

H-index: 3

I10-index: 1